ARCE
Dead / Abandoned — Abandoned — no statement of use filed (as of 08 Sept 2025)
What this means for you
This application is over — abandoned 08 Sept 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90431302
- Mark type
- Stylized text
- Filed
- 30 Dec 2020
- Published for opposition
- 14 Dec 2021
- Abandoned
- 08 Sept 2025
- Attorney of record
- Zhi Dong
Goods and services
- Class 005 — Pharmaceuticals: Biological preparations for medical purposes, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological preparations for veterinary purposes for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological tissue cultures for medical purposes, namely, human blood samples, human allograft tissues, human umbilical cord blood and human induced pluripotent stem cells (iPSCs) from somatic cells; biological tissue cultures for veterinary purposes, namely, animal blood samples, tumors and allograft tissues; blood for medical purposes; cultures of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical purposes, namely, chemical and biological reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; pharmaceuticals, namely, drugs for medical purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; enzymes for medical purposes; enzymes for veterinary purposes; immunostimulants; medicinal infusions for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for human purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for veterinary purposes, namely, for veterinary cancers; preparations of microorganisms for medical or veterinary use, namely, cultures of bacteria and viruses for medical or veterinary use; pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceutical preparations, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals in the nature of pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; transplants comprised of living cells, namely, genetically engineered tissues for medical and transplant purposes; genetically engineered cells for medical purposes, specifically for transplantation purposes; vaccines
Owner
- ARCE THERAPEUTICS, INC., Taipei City, TW
- ARCE THERAPEUTICS, INC., Taipei City, TW
Prosecution history
- 08 Sept 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 08 Sept 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 22 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Apr 2025 — SOU EXTENSION 5 GRANTED
- 23 Jan 2025 — SOU EXTENSION 5 FILED
- 21 Apr 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 23 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Jul 2024 — SOU EXTENSION 4 GRANTED
- 19 Jul 2024 — SOU EXTENSION 4 FILED
- 19 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 02 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Jan 2024 — SOU EXTENSION 3 GRANTED
- 31 Jan 2024 — SOU EXTENSION 3 FILED
- 31 Jan 2024 — SOU TEAS EXTENSION RECEIVED